跳至主要内容
临床试验/NCT03765944
NCT03765944已完成1 期

A Single Dose, Randomized, Open-label, 2-Period, 2-way Crossover, Bioequivalence Study of Sirolimus Granules and Sirolimus Tablets in Japanese Healthy Adults

Nobelpharma1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年12月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
Blood sirolimus concentration

研究概览

简要总结

The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
20 Years 至 39 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Japanese healthy subjects aged 20 to 39 years of age
  • Subjects with BMI ≥ 18.5 kg/m2 and < 25.0 kg/m2
  • Subjects who are considered by the investigator as suitable for participation in the trial from lab test results at screening
  • Subjects who are considered by the investigator as suitable for participation in the trial from lab test results on the day before administration
  • Subjects who write informed consent
  • Subjects who are able to comply with the study requirements during the study period

排除标准

  • Subjects who have a history of hypersensitivity to sirolimus or sirolimus derivative
  • Subjects who have a history of hypersensitivity or allergies to other drug
  • SUbjects who have an acute or chronic infectious diseases
  • Subjects who have a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments
  • Subjects who have diagnosed with alcoholism or a history of alcoholism
  • Subjects who have an abnormal findings (pneumonia, etc) from the result of chest CT at screening
  • Subjects who have been administered other investigational drug within 12 weeks before the initial administration
  • Subjects who have performed blood collection or donation as follows
  • Collected or donated 200 ml or more whole blood within 4 weeks before the initial administration
  • Male subject; collected or donated more than 400 mL whole blood within 12 weeks before the initial administration
  • Female subjects; collected or donated more than 400 mL whole blood within 16 weeks before the initial administration
  • Collected or donated blood component within 2 weeks before the initial administration
  • Subjects who have positive results for HBs antigen, HBs antibody, HBc antibody, HCV antibody, HIV antigen/antibody, or syphilis
  • Subjects who received any non-prescription or prescription drug within 12 weeks before the initial administration
  • Subjects who are pregnant/lactating, or do not agree to contraception during the period from the screening until 8 weeks after the final administration due to planning to become pregnant
  • Subjects who cannot speak, read and write in Japanese
  • Subjects who are considered by the investigator as unsuitable for participation in the trial

研究组 & 干预措施

NPC-12 granule

Active Comparator

NPC-12 granules (1.0g: 2mg sirolimus)

干预措施: sirolimus (Drug)

NPC-12T tablet

Active Comparator

NPC-12T 2 tablets (2mg sirolimus)

干预措施: sirolimus (Drug)

结局指标

主要结局

Blood sirolimus concentration

时间窗: Pre-dose and post-dose (0.5, 1, 1.5, 2, 4, 8, 12, 18, 24, 48 and 72 hours)

Whole blood concentration of sirolimus will be measured and compared between NPC-12 granules and NPC-12T tablets.

次要结局

未报告次要终点

研究者

发起方
Nobelpharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Bioequivalence Study of NPC-12 (Sirolimus) Granules... | 临床试验